Ovarian Cancer Biomarkers : Mapping to Improve Outcomes / edited by Khalid El Bairi
Contributor(s): El Bairi, Khalid, editor literario
Material type:
E-bookSeries: (Biomedical and Life Sciences (SpringerNature-11642)); (Biomedical and Life Sciences (R0) (SpringerNature-43708)).Publisher: Singapore : Springer International Publishing, 2021Edition: First edition 2021.Description: 1 recurso en línea (XV, 229 páginas) : 9 ilustraciones, 8 ilustraciones a color.ISBN: 9789811618734.Subject: Ovarios -- Cáncer
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC280 .O8 2021 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.18122408 |
Chapter 1. General Overview of the Origins and Pathology of Ovarian Cancer -- Chapter 2_An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology -- Chapter 3_The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways and Predictive Biomarkers -- Chapter 4_Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes -- Chapter 5_The Emergence of Circulating Tumor DNA in the Management of Ovarian Cancer -- Chapter 6_Proteomic Biomarkers for Early Detection and Patients' Stratification in Ovarian Cancer -- Chapter 7_Cutting-edge Technologies and Ovarian Cancer.
This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.
There are no comments on this title.